Nuclear Scintigraphy of the skeleton (bone scintigraphy or bone scan)

2009 ◽  
pp. 150-150
Keyword(s):  
Bone Scintigraphy ◽  
Bone Scan ◽  
Nuclear Scintigraphy

Bone Scintigraphy in the Evaluation of Children With Obscure Skeletal Pain

PEDIATRICS ◽  
1987 ◽  
Vol 79 (4) ◽  
pp. 587-592
Author(s):  
Deborah C. ter Meulen ◽  
Massoud Majd
Keyword(s):  
Rheumatoid Arthritis ◽  
Bone Scintigraphy ◽  
Inflammatory Disease ◽  
Joint Pain ◽  
Bone Scan ◽  
Skeletal Disease ◽  
Skeletal Pain ◽  
Bone Scans ◽  
Cause Of Pain

A retrospective analysis of bone scans of 381 children with unexplained skeletal pain was made. Of these, findings are reported on 358 for whom there were sufficient clinical data. The bone scan results suggested trauma as the cause of pain in 43 patients, inflammatory disease in 73 patients, and neoplasia in ten patients. There was only one false-positive bone scan. Normal findings were obtained from 227 patients, in whom no significant skeletal disease was detected on follow-up, except for juvenile rheumatoid arthritis in 23 patients. Bone scintigraphy is, therefore, an important, noninvasive diagnostic test for evaluating children with obscure bone or joint pain. We recommend that this test be performed early in the evaluation of these children to arrive at the diagnosis expeditiously and with minimal patient discomfort and morbidity.

Fully automated analysis for bone scintigraphy with artificial neural network: usefulness of bone scan index (BSI) in breast cancer

2019 ◽  
Vol 33 (10) ◽  
pp. 755-765 ◽  
Author(s):  
Anri Inaki ◽  
Kenichi Nakajima ◽  
Hiroshi Wakabayashi ◽  
Takafumi Mochizuki ◽  
Seigo Kinuya
Keyword(s):  
Breast Cancer ◽  
Neural Network ◽  
Artificial Neural Network ◽  
Bone Scintigraphy ◽  
Bone Scan ◽  
Automated Analysis ◽  
Bone Scan Index ◽  
Artificial Neural

Scintigraphic detection of sequential symmetrical metatarsal stress fractures

1995 ◽  
Vol 85 (3) ◽  
pp. 162-165 ◽  
Author(s):  
NH Patel ◽  
AF Jacobson ◽  
J Williams
Keyword(s):  
Bone Scintigraphy ◽  
Stress Fracture ◽  
Bone Scan ◽  
Stress Fractures ◽  
Foot Pain ◽  
Plain Radiographs ◽  
Three Phase ◽  
Second Metatarsal ◽  
Bone Abnormalities

A patient with complaints of right foot pain and previous normal radiographs had an abnormal three-phase bone scan consistent with a second metatarsal stress fracture. Subsequent radiographs confirmed this diagnosis. Two months later, the patient developed pain in his left foot, and again initial radiographs were noncontributory. A later bone scan revealed a left second metatarsal stress fracture. The results in this case reemphasize the value of bone scintigraphy in patients with foot pain and no bone abnormalities on plain radiographs.

Diagnosis and semiquantification of osteonecrosis of the jaw by bone scan index on bone scintigraphy.

2016 ◽  
Vol 34 (2_suppl) ◽  
pp. e639-e639
Author(s):  
Hiroshi Yaegashi ◽  
Atsushi Mizokami ◽  
Satoru Watanabe ◽  
Kenichi Nakajima ◽  
Natsuyo Noguchi ◽  
...  
Keyword(s):  
Prostate Cancer ◽  
Early Detection ◽  
Bone Scintigraphy ◽  
Renal Cancer ◽  
Bone Scan ◽  
Osteonecrosis Of The Jaw ◽  
Bone Scan Index ◽  
Reactive Protein ◽  
Skeletal Related Event

e639 Background: Bone management is extremely important for maintaining QOL of prostate or renal cancer patients with bone metastasis. Physicians often administrate bone modifying agents (BMA), zoledronic acid or denosumab, to prevent skeletal-related event and bone pain for such patients. However, osteonecrosis of the jaw (ONJ) is one of sever adverse events of BMA (Medication-related ONJ; MRONJ). The early detection and follow-up of ONJ is extremely important issue. In order to achieve this issue, we utilized bone scintigraphy and a computer-aided diagnosis using a bone scan index (BSI). Methods: A total of 22 patients with either prostate cancer or renal cancer (27 lesions) diagnosed with MRONJ after treatment with BMA were investigated. Median age was 72.5 years (range 52-82 years). The primary disease was prostate cancer (81.8%), renal cancer (18.2%). Regarding the treatment, 86.4% of the patients were treated with bisphosphonate drugs, none in denosumab, and both in 13.6%, respectively. The median duration of medication was 33 months (range 7-70 months) by the time of MRONJ diagnosis. All patients underwent Tc-99m methylene diphosphonate bone scintigraphy. Bone uptake in the jaw was analyzed using BSI, which was calculated by BONENAVI (FUJIFILM RI Pharma, Japan; EXINIbone, EXINI Diagnostics, Sweden). Significant hot spots were manually selected according to both serial scintigraphic images and dental records, and the fraction of them to the entire skeleton was referred as BSI of the jaw (BSIJ). The level of BSIJ was evaluated in comparison with stage of ONJ and inflammation marker, C-reactive protein (CRP). Results: The median BSIJ of lesions was 0.14 (range 0.00-0.43) at the time of MRONJ diagnosis. If MRONJ is not treated appropriately, BSIJ tended to increase during treatment with BMA. When patients were classified according to their clinical stages of MRONJ, higher stage MRONJ lesions had significantly higher BSIJ (p < 0.01). In addition, BSIJ was correlated with CRP. Conclusions: Evaluation of BSIJ using BONENAVI on bone scintigraphy was helpful for early detection and follow-up of MRONJ. Furthermore, increased BSIJ on bone scintigraphy were related to CRP and stage of ONJ.

Evaluation of bone metastasis of castration-resistant prostate cancer after enzalutamide and abiraterone using Bone Scan Index on bone scintigraphy.

2017 ◽  
Vol 35 (6_suppl) ◽  
pp. e596-e596
Author(s):  
Suguru Kadomoto ◽  
Kouji Izumi ◽  
Takahiro Nohara ◽  
Konaka Hiroyuki ◽  
Yoshifumi Kadono ◽  
...  
Keyword(s):  
Prostate Cancer ◽  
Bone Metastasis ◽  
Bone Metastases ◽  
Bone Scintigraphy ◽  
Bone Scan ◽  
Average Rate ◽  
Castration Resistant Prostate Cancer ◽  
Bone Scan Index ◽  
Castration Resistant ◽  
Better Than

e596 Background: It was ambiguous till now to evaluate the change of bone metastasis by various treatments. To quantify the change of bone metastases by enzalutamide, abiraterone, and docetaxel for the castration-resistant prostate cancer (CRPC) with bone metastases (bmCRPC), we employed Bone Scan Index (BSI) on bone scintigraphy. Methods: We retrospectively evaluated the change of PSA and bone metastases of CRPC patients who were treated with enzalutamide (Enz), abiraterone (Abi) and/or docetaxel (DOC) in our hospital. All patients underwent Tc-99m MDP bone scintigraphy. The degree of bone metastases was analyzed using BSI, which was calculated by BONENAVI (FUJIFILM RI Pharma, Japan; EXINIbone, EXINI Diagnostics, Sweden). 19 patients were treated with enzalutamide (8 cases: pre-docetaxel, 11 cases: post-docetaxel). The median PSA of patients treated with Enz was 12.64 ng/ml (1.63-199 ng/ml). And 11 patients were treated with abiraterone (5 cases: pre-docetaxel, 6 cases: post-docetaxel). The median PSA of patients treated with Abi was 26.37 ng/ml (2.29-199 ng/ml). Results: We observed decline of PSA in 18/30 cases (9 cases: pre-DOC, 9 cases: post-DOC). Decline of PSA to 50% or more was observed in 14 cases. In contrast, decline of BSI was observed in 53.3% (16/30) cases and decline of PSA to 25% or more was observed in only 6 cases. BSI decreased in 84.6% (11/13) of pre-DOC setting and in 29.4% (5/17) of post-DOC setting indicating that change of BSI was poor in post-DOC setting. However, DOC had already decreased BSI in 91.7% (11/12) before Abi or Enz treatment. Moreover, the average rate of BSI decline in the patients that BSI decreased by DOC was better than the patients that BSI decreased by Abi/Enz (-48.46% vs -28.56%). Finally, although the rate of BSI change by Enz was weakly correlated with the rate of PSA decline (y = 0.3906x + 25.35, R2 = 0.3423), BSI continued to increase in four cases in spite of PSA decline. Conclusions: BSI using BONENAVI on bone scintigraphy was helpful for evaluating the effectiveness of treatment and following-up of bmCRPC.

scholarly journals Nuclear Scintigraphy (Bone Scan) for the Horse

EDIS ◽  
2013 ◽  
Vol 2013 (6) ◽  
Author(s):  
Alison Morton
Keyword(s):  
Bone Scan ◽  
Poor Performance ◽  
University Of Florida ◽  
Nuclear Scintigraphy ◽  
Full Color ◽  
Imaging Service ◽  
The University

The veterinarians of the University of Florida Equine Lameness & Imaging Service specialize in the treatment and rehabilitation of poor performance in sport horses. This series of one-page full color fact sheets describes various diagnostic and imaging services available for diagnosing and treating lameness issues in horses. http://edis.ifas.ufl.edu/topic_series_equine_lameness_and_imaging_service

scholarly journals HYBRID BONE SCINTIGRAPHY IN GASTROINTESTINAL MALIGNANCIES – INSTITUTIONAL EXPERIENCE

2018 ◽  
Vol 4 (1) ◽  
Author(s):  
Nazia Rashid ◽  
Saima Riaz ◽  
Humayun Bashir ◽  
Shafqat Mehmood
Keyword(s):  
Bone Metastases ◽  
Bone Scintigraphy ◽  
Bone Scan ◽  
Axial Skeleton ◽  
Emission Computed Tomography ◽  
Appendicular Skeleton ◽  
Osseous Metastasis ◽  
Gastrointestinal Malignancies ◽  
Metastatic Lesions ◽  
Bone Scans

Objective: Bone metastases in gastrointestinal (GI) malignancies are uncommon and known to be predominantly lytic thus rendering a limited role for conventional bone scintigraphy. The aim of the study is to review Tc99m MDP bone scans performed in patients with known GI malignancy and the utility of Single-photon emission computed tomography (SPECT)/CT in characterization of bone lesions.Methods: Retrospective review of bone scans was done from June 2014 to December 2016 in patients with known GI malignancy, using electronic Hospital Information System.Results: A total of 110 patients (60 males, 50 females; Age range: 22–84 years, Mean Age 51.4 years with SD of 14.8) had bone scan over a period of 30 months. The commonest indications for referral were suspected bone metastasis on other imaging modalities including [CT (n = 56), Magnetic resonance imaging (n = 10), Positron emission tomography/CT (n = 6)], musculoskeletal pain (n = 37), pathological fracture (n = 1), neurological symptoms (n = 1), hypercalcemia (n = 1) and others (n =14) including restaging workup etc. Metastatic lesions were identified in 32 (29%) patients whereas 78 (71%) patients had benign non-aggressive lesions leading to normal bone scans. Among 32 patients with osseous metastasis, 8 (25%) patients had unifocal lesion; axial skeleton (n = 2) appendicular skeleton (n = 6), 24 (75%) patients had multifocal lesions; axial skeleton (n = 6), appendicular skeleton (n = 6) and both axial + appendicular (n = 12). Four (12%) patients had concurrent visceral metastases. In our cohort, based on the location of primary tumour, the frequencies of osseous metastasis were; esophagus = 15 out of 43 (35%), gastric = 7 out of 18 (39 %), gastro-esophageal junction = 1 out of 8 (1.5%) and colorectal = 9 out of 40 (22.5). SPECT/CT was acquired in 29 out of 110 patients, which characterized metastatic lesions (n = 12) and benign looking non-aggressive entities (n =17). Overall, bone scan upstaged disease in 31% and down staged 15% patients.Conclusion: Bone metastases in GI malignancies, though uncommon, show an aggressive pattern, with axial and appendicular involvement, and can be readily identified with hybrid bone scintigraphy in symptomatic patients. Key words: Hybrid imaging, Tc99m MDP, bone metastases, gastrointestinal malignancies

scholarly journals SURVIVAL IMPACT OF SKELETAL METASTASIS ON BONE SCINTIGRAPHY IN PATIENTS WITH GERM CELL TUMOURS

2016 ◽  
Vol 2 (4) ◽  
Author(s):  
Maimoona Siddique ◽  
Aamna Hassan ◽  
Saadiya J Khan
Keyword(s):  
Germ Cell ◽  
Bone Metastases ◽  
Bone Scintigraphy ◽  
Bone Scan ◽  
Disease Free Survival ◽  
Skeletal Metastasis ◽  
Whole Body ◽  
Skeletal Metastases ◽  
Germ Cell Tumours ◽  
Visceral Metastases

Objective: Our aim was to determine the frequency of skeletal metastasis in germ cell tumours (GCT) at baseline and relapse on conventional technetium-99m methylene diphosphonate (Tc-99m MDP) whole body bone scan (bone scan) and to evaluate the effect of bone metastases on survival. Materials and Methods: Electronic medical records of histologically proven GCT over 64 months were retrospectively analysed. Basic demographic and histologic information were correlated with the presence of osseous and visceral metastases. 5-year disease-free survival (DFS) and overall survival (OS) were calculated in presence, the absence of bone metastases at baseline and at relapse. Results: A total of 130 gonadal and extragonadal GCT patients underwent Tc-99m MDP bone scans; four with insuf cient data were excluded from the study. 47% were females and 53% were males with the age range of 1 month – 72 years. 105 (83%) were under 18 years of age. Osseous metastasis was detected in 12 (9.5%). Two (17%) had solitary and 10 (83%) had multifocal skeletal metastases. Clinically, 83% had localised bone pain. Osseous metastases were more frequently associated with mixed GCT and yolk sac tumour. 50% of mediastinal GCT developed bone metastases. 42% died within 4–18 months. There was a statistically signi cant impact of visceral metastases on DFS and OS. OS at 5 years in patients without bone metastases, with bone metastases at baseline and bone metastases at relapse, was 77%, 38% and 75%, respectively. 5-year DFS for the same cohort groups was 63%, 38% and 20%, respectively. Conclusion: Osseous involvement was found in 9.5% of GCT patients undergoing diagnostic Tc-99m MDP bone scan. Baseline skeletal evaluation for metastases should be done, particularly in the case of bone pains or known systemic metastases. Although skeletal relapses are rare, they have a grim outcome. Key words: Bone scintigraphy, germ cell tumours, skeletal metastases 

scholarly journals Bilateral lungs uptake of 99mTc-HDP in a post treated patient with breast carcinoma

2018 ◽  
Vol 2 (1) ◽  
pp. 55-57
Author(s):  
Ajay Kumar Yadav ◽  
Raj Narayan Ray ◽  
Swechchha Joshi ◽  
Quamrul Haque Ansari ◽  
YUAN Gengbiao
Keyword(s):  
Renal Function ◽  
Breast Carcinoma ◽  
Bone Scintigraphy ◽  
Bone Scan ◽  
Treated Patient ◽  
Chemotherapy Treatment ◽  
Poor Renal Function

 99mTc-HDP radiopharmaceuticals uptake has been reported at various sites and it is known to be induced by various causes. Bilateral lungs uptake of 99mTc-HDP in a post treated patient with breast carcinoma can be a cause of poor renal function as chemotherapy affects renal function. Here we report on a post treated patient with Ca Breast in which rarely having 99mTc-HDP uptake in bilateral lungs. After full cycle of chemotherapy treatment, some patient suffer with poor renal function although it will improve along with time but due to poor renal function there is chance of 99mTc-HDP uptake in lungs during bone Scintigraphy. So Bilateral lungs uptake of 99mTc-HDP in a post treated patient with breast carcinoma on bone scan may suggest rare but due to poor renal function which some time develop after full cycle chemotherapy treatment.

Study of the Usefulness of Bone Scan Index Calculated From 99m-Technetium-Hydroxymethylene Diphosphonate (99mtc-HMDP) Bone Scintigraphy for Bone Metastases from Prostate Cancer Using Deep Learning Algorithms

2020 ◽  
Vol 16 ◽  
Author(s):  
Shigeaki Higashiyama ◽  
Atsushi Yoshida ◽  
Joji Kawabe
Keyword(s):  
Prostate Cancer ◽  
Deep Learning ◽  
Bone Metastasis ◽  
Bone Metastases ◽  
Bone Scintigraphy ◽  
Bone Scan ◽  
Learning Algorithms ◽  
Bone Imaging ◽  
Bone Scan Index ◽  
Metabolic Biomarkers

Background: BSI calculated from bone scintigraphy using 99mtechnetium-methylene diphosphonate (99mTc-MDP) is used as a quantitative indicator of metastatic bone involvement in bone metastasis diagnosis, therapeutic effect assessment, and prognosis prediction. However, the BONE NAVI, which calculates BSI, only supports bone scintigraphy using 99mTc-MDP. Aims: We developed a method in collaboration with the Tokyo University of Agriculture and Technology to calculate bone scan index (BSI) employing deep learning algorithms with bone scintigraphy images using 99mtechnetiumhydroxymethylene diphosphonate (99mTc-HMDP). We used a convolutional neural network (CNN) enabling the simultaneous processing of anterior and posterior bone scintigraphy images named CNNapis. Objectives: The purpose of this study is to investigate the usefulness of the BSI calculated by CNNapis as bone imaging and bone metabolic biomarkers in patients with bone metastases from prostate cancer. Methods: At our hospital, 121 bone scintigraphy scans using 99mTc-HMDP were performed and analyzed to examine bone metastases from prostate cancer, revealing the abnormal accumulation of radioisotope (RI) at bone metastasis sites. Blood tests for serum prostate-specific antigen (PSA) and alkaline phosphatase (ALP) were performed concurrently. BSI values calculated by CNNapis were used to quantify the metastatic bone tumor involvement. Correlations between BSI and PSA and between BSI and ALP were calculated. Subjects were divided into four groups by BSI values (Group 1, 0 to <1; Group 2, 1 to <3; Group 3, 3 to <10; Group 4, >10), and the PSA and ALP values in each group were statistically compared. Results: Patients diagnosed with bone metastases after bone scintigraphy were also diagnosed with bone metastases using CNNapis. BSI corresponding to the range of abnormal RI accumulation was calculated. PSA and BSI (r = 0.2791) and ALP and BSI (r = 0.6814) correlated positively. Significant intergroup differences in PSA between Groups 1 and 2, Groups 1 and 4, Groups 2 and 3, and Groups 3 and 4 and in ALP between Groups 1 and 4, Groups 2 and 4, and Groups 3 and 4 were found. Conclusion : BSI calculated using CNNapis correlated with ALP and PSA values and is useful as bone imaging and bone metabolic biomarkers, indicative of the activity and spread of bone metastases from prostate cancer.

Sign in / Sign up

Export Citation Format

Share Document